Market Cap 1.43B
Revenue (ttm) 47.07M
Net Income (ttm) -223.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475.59%
Debt to Equity Ratio 0.00
Volume 500,900
Avg Vol 767,112
Day's Range N/A - N/A
Shares Out 64.94M
Stochastic %K 93%
Beta 2.22
Analysts Strong Sell
Price Target $57.63

Latest News on KYMR

Kymera: Protein Degradation Could Drive Dupixent-Like Value

Dec 7, 2024, 1:07 AM EST - 5 months ago

Kymera: Protein Degradation Could Drive Dupixent-Like Value


Kymera Therapeutics Announces Proposed Public Offering

Aug 19, 2024, 4:01 PM EDT - 8 months ago

Kymera Therapeutics Announces Proposed Public Offering


Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 11:23 AM EDT - 9 months ago

Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript